Skip to content

Masseter hypertrophy

Masseter hypertrophy refers to enlargement or prominence of the masseter muscle, often discussed in relation to lower-face contouring and jawline shape. In botulinum toxin practice, it is commonly associated with aesthetic treatment but may also overlap with functional concerns such as jaw tension.

This indication is useful because it connects facial anatomy, muscle activity, and aesthetic strategy within the broader botulinum toxin field. It also shows that indication logic can differ from classic wrinkle treatment even when the same toxin family is used.

Masseter hypertrophy is frequently discussed in aesthetic medicine, especially in markets where lower-face contouring is a prominent treatment goal. Approval status, common practice patterns, and terminology vary by region, so this topic should be interpreted conservatively rather than as a universally standardized indication.

Treatment planning focuses on the size and function of the masseter, facial proportions, and the need to preserve comfortable chewing while reducing excessive prominence. Brand identity matters because unit systems and formulation context differ across products. The dilution and reconstitution page helps frame how muscle size, injection plan, and treatment objective alter interpretation. The dose calculation overview page adds the session-structure and site-distribution logic that sits behind lower-face planning.

Lower-face treatment raises different practical issues from upper-face wrinkle care, including bite comfort, smile balance, and the possibility of a result that feels too weak or too subtle. Regional practice norms also differ, so readers should avoid assuming the same indication framing applies everywhere. The injection anatomy overview page frames that lower-face anatomy against upper-face, cervical, and limb treatment contexts. The safety and adverse-effect framing page adds the functional-risk context behind chewing and smile-related tradeoffs.